Global Squamous Cell Carcinoma of the Head and Neck Treatment Market, By Drug Class (Immunotherapy, Chemotherapy, Targeted Therapy), Type (Salivary Gland, Oral and Oropharyngeal, Nasal Cavity, and Paranasal Sinuses, Nasopharyngeal, Laryngeal, and Hypo Pharyngeal), Diagnosis (Bioscopy Screening Tests, Blood Tests, Dental Diagnosis, Imaging, Endoscopy), Treatment (Radiation, Surgery, Chemotherapy, Immunotherapy), Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors, Mitotic Inhibitors), Distribution Channel (Online, Offline), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers) – Industry Trends and Forecast to 2030.
Squamous Cell Carcinoma of the Head and Neck Treatment Market Analysis and Size
The growing incidence of head and neck cancer is expected to boost the market growth. As per the American Society of Clinical Oncology (ASCO), in the U.S., around 4% of all cancer cases are associated with the head and neck. It has been witnessed over the years that the oral route of administration is anticipated to be the fastest-growing segment during the forecast period because of the increasing oral therapeutics drugs for the treatment of patients suffering from head and neck cancer.
Data Bridge Market Research analyses that the squamous cell carcinoma of the head and neck treatment market, which was USD 12 billion in 2022, would rise to USD 24.80 billion by 2030 and is expected to undergo a CAGR of 9.50% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Squamous Cell Carcinoma of the Head and Neck Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Immunotherapy, Chemotherapy, Targeted Therapy), Type (Salivary Gland, Oral and Oropharyngeal, Nasal Cavity and Paranasal Sinus, Nasopharyngeal, Laryngeal, and Hypo Pharyngeal), Diagnosis (Bioscopy Screening Tests, Blood Tests, Dental Diagnosis, Imaging, Endoscopy), Treatment (Radiation, Surgery, Chemotherapy, Immunotherapy), Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors, Mitotic Inhibitors), Distribution Channel (Online, Offline), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers)
|
|
Countries Covered
|
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Boehringer Ingelheim International GmbH. (Germany), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd (Israel), AbbVie Inc (U.S.), Astellas Pharma Inc. (Japan), Sumitomo Pharma Co., Ltd (Japan), Amgen Inc (U.S.), Curis, Inc (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Squamous cell carcinoma of the head and neck is the most prevalent form of skin cancer that initiates from the squamous cells in the skin's middle and outer layers. It is caused either by long exposure to harmful ultraviolet (UV) radiation or maybe for other idiopathic reasons. The squamous cell carcinoma of the head and neck treatment deals with the treatment process of the disease by surgery, radiation, chemotherapy, or immunotherapy.
Global Squamous Cell Carcinoma of the Head and Neck Treatment Market Dynamics
Drivers
- Increasing R&D for Cancer Drugs and Treatment
Head and neck cancers are mostly treated by single or combination therapies. Healthcare providers are continuously developing drugs and treatments for treating the disease due to the presence of varied types of head and neck cancers. Presently, numerous cancer vaccines for treating head and cancer drugs are under different phases of clinical trials. Pharmaceutical manufacturers are investing a lot in research and development to cure the disease properly. The Food and Drug Administration (FDA) has approved numerous drugs for treating head and neck cancer. This factor leads to the growth of the market.
- Increasing Adoption of Immune Therapeutics
Immune therapeutics or immunotherapy is offered to cancer patients as it holds various benefits over other therapy types. With the increasing concern for the growing number of cancer cases, there is an increasing need to treat these patients. Immunotherapy is widely used in these patients as it helps the body prevent cancer with its natural defenses. Thus, this factor help in the market growth.
Opportunities
- Increasing Demand for Injectable Administration
The huge growth of injectable route of administration increases the market growth. This can be due to the huge availability of HNC therapeutic drugs in injectable form, better availability, and increased efficiency of injectable drugs. There are a huge number of drugs that are available in injectable form. For instance, Keytruda, manufactured by Merck & Co., Inc., is administered intravenously as an infusion in patients suffering from head and neck cancer. Thus, this factor boosts market growth.
- Increasing Strategic Developments Associated with Squamous Cell Carcinoma of the Head and Neck Treatment
Market players are adopting various strategies for market growth, such as mergers and acquisitions. For instance, Sanofi acquired Amunix Pharmaceuticals, Inc. at USD 1 billion in 2021. This acquisition boosts the company's oncology product portfolio and provides a high-growth opportunity. Therefore, this factor acts as a major factor that increases market growth.
Restraints/Challenges
- High Cost of Head and Neck Treatment Drugs
Treating this cancer is very costly, particularly for individuals from -low and -middle-income groups. Furthermore, the unavailability of proper healthcare standards in numerous nations is also expected to decrease the demand for head and neck squamous cell carcinoma (HNSCC) treatment and drugs. The increasing cost of treatment and drugs is anticipated to impede market growth during the forecast period.
This squamous cell carcinoma of the head and neck treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the squamous cell carcinoma of the head and neck treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In 2021, the U.S. FDA granted the breakthrough therapy designation for Tipifarnib, developed by Kura Oncology, Inc., for treating patients suffering from head and neck squamous cell carcinoma (HNSCC). This is a selective, potent, and orally administered drug.
Global Squamous Cell Carcinoma of the Head and Neck Treatment Market Scope
The squamous cell carcinoma of the head and neck treatment market is segmented on the basis of drug class, type, diagnosis, treatment, therapeutic class distribution channel and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Immunotherapy
- Chemotherapy
- Targeted Therapy
Type
- Salivary Gland
- Oral and Oropharyngeal
- Nasal Cavity and Paranasal Sinus
- Nasopharyngeal
- Laryngeal
- Hypo Pharyngeal
Diagnosis
- Bioscopy Screening Tests
- Blood Tests
- Dental Diagnosis
- Imaging
- Endoscopy
Treatment
- Radiation
- Surgery
- Chemotherapy
- Immunotherapy
Therapeutic Class
- PD Inhibitors
- EGFR Inhibitors
- Microtubule Inhibitors
- Mitotic Inhibitors
Distribution Channel
- Online
- Offline
End User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
Squamous Cell Carcinoma of the Head and Neck Treatment Market Regional Analysis/Insights
The squamous cell carcinoma of the head and neck treatment market is analyzed and market size insights and trends are provided by drug class, type, diagnosis, treatment, therapeutic class distribution channel and end user as referenced above.
The countries covered in the squamous cell carcinoma of the head and neck treatment market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to grow during the forecast period the squamous cell carcinoma of the head and neck treatment market because of the growing population, lifestyle, and adoption of advanced technologies. The growing elderly populations and growing prescription of immunotherapy drugs such as Pembrolizumab (Keytruda) and Nivolumab (Opdivo) used to treat numerous types of HNC are anticipated to boost the market growth in upcoming years.
North America dominates the market in the forecast period because of the growing levels of investment in developing advanced technologies such as platinum-based therapy in this region. Also, government support for the development of the healthcare sector is helping in the market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The squamous cell carcinoma of the head and neck treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for squamous cell carcinoma of the head and neck treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the squamous cell carcinoma of the head and neck treatment market. The data is available for historic period 2011-2021.
Competitive Landscape and Squamous Cell Carcinoma of the Head and Neck Treatment Market Share Analysis
The squamous cell carcinoma of the head and neck treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to squamous cell carcinoma of the head and neck treatment market.
Some of the major players operating in the squamous cell carcinoma of the head and neck treatment market are:
- Sanofi (France)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Boehringer Ingelheim International GmbH. (Germany)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Teva Pharmaceutical Industries Ltd (Israel)
- AbbVie Inc (U.S.)
- Astellas Pharma Inc. (Japan)
- Sumitomo Pharma Co., Ltd (Japan)
- Amgen Inc (U.S.)
- Curis, Inc (U.S.)
SKU-